TJ Cradick

Company: Gene Editing Frontiers

Job title: CSO, Principal

Seminars:

The Future: How Baby KJ’s Personalized CRISPR Therapy Will Facilitate Better Rare Disease Targeting 9:35 am

Following the groundbreaking work to launch the world’s first personalized CRISPR therapy to treat baby KJ, a new blueprint for rare disease treatment is forming. With the baby KJ team swiftly adapting base editing technology, rapidly co-ordinating regulatory approval and redefining clinical strategies, this session offers an unmissable insight into how this pioneering approach to…Read more

day: Pre-Conference Workshop Day